Disc Medicine to Host Conference Call on Type C Meeting for Bitopertin in Erythropoietic Protoporphyria (EPP)
Disc Medicine (NASDAQ:IRON) has announced a conference call scheduled for Tuesday, January 21, at 8:00 am EST to discuss feedback from its Type C meeting with the FDA regarding bitopertin in Erythropoietic Protoporphyria (EPP). The company, which focuses on developing treatments for serious hematologic diseases, will host the discussion to share insights from their regulatory interaction.
Interested participants can register for the event through the Events and Presentations section of Disc Medicine's investor relations website. This meeting represents a significant step in the development process for bitopertin as a potential treatment for EPP patients.
Disc Medicine (NASDAQ:IRON) ha annunciato una conferenza telefonica programmata per martedì 21 gennaio alle 8:00 EST per discutere il feedback ricevuto durante il suo incontro di Tipo C con la FDA riguardo a bitopertin nell'Eritropoietic Protoporphyria (EPP). L'azienda, che si concentra sullo sviluppo di trattamenti per malattie ematologiche gravi, ospiterà la discussione per condividere approfondimenti riguardanti la loro interazione normativa.
Gli interessati possono registrarsi per l'evento attraverso la sezione Eventi e Presentazioni del sito web delle relazioni con gli investitori di Disc Medicine. Questo incontro rappresenta un passo significativo nel processo di sviluppo di bitopertin come potenziale trattamento per i pazienti affetti da EPP.
Disc Medicine (NASDAQ:IRON) ha anunciado una conferencia telefónica programada para el martes 21 de enero a las 8:00 am EST para discutir los comentarios de su reunión de Tipo C con la FDA sobre bitopertin en la Protoporfiria Eritropoietica (EPP). La compañía, que se centra en desarrollar tratamientos para enfermedades hematológicas graves, llevará a cabo la discusión para compartir ideas sobre su interacción regulatoria.
Los participantes interesados pueden registrarse para el evento a través de la sección de Eventos y Presentaciones en el sitio web de relaciones con inversores de Disc Medicine. Esta reunión representa un paso significativo en el proceso de desarrollo de bitopertin como un tratamiento potencial para los pacientes con EPP.
Disc Medicine (NASDAQ:IRON)은 1월 21일 화요일 오전 8시 EST에 FDA와의 타입 C 미팅에 대한 피드백을 논의하기 위한 콘퍼런스 콜을 발표했습니다. 중증 혈액 질환 치료제 개발에 집중하는 이 회사는 규제 상호작용에 대한 인사이트를 공유하기 위해 논의를 주최할 것입니다.
관심 있는 참가자는 Disc Medicine의 투자자 관계 웹사이트의 이벤트 및 발표 섹션을 통해 행사에 등록할 수 있습니다. 이번 회의는 EPP 환자를 위한 잠재적 치료제로서 bitopertin 개발 과정에서 중요한 단계를 나타냅니다.
Disc Medicine (NASDAQ:IRON) a annoncé une conférence téléphonique prévue pour le mardi 21 janvier à 8h00 EST afin de discuter des retours de sa réunion de Type C avec la FDA concernant le bitopertin dans la Protoporphyrie Érythropoïétique (EPP). L'entreprise, qui se concentre sur le développement de traitements pour des maladies hématologiques graves, animera la discussion pour partager des informations de leur interaction réglementaire.
Les participants intéressés peuvent s'inscrire à l'événement via la section Événements et Présentations du site web des relations investisseurs de Disc Medicine. Cette réunion représente une étape significative dans le processus de développement du bitopertin en tant que traitement potentiel pour les patients atteints d'EPP.
Disc Medicine (NASDAQ:IRON) hat einen Telefonkonferenztermin für Dienstag, den 21. Januar, um 8:00 Uhr EST angekündigt, um das Feedback aus ihrem Typ-C-Treffen mit der FDA bezüglich Bitopertin bei der erythropoetischen Protoporphyrie (EPP) zu erörtern. Das Unternehmen, das sich auf die Entwicklung von Behandlungen für schwerwiegende hämatologische Erkrankungen konzentriert, wird die Diskussion moderieren, um Einblicke aus ihrer regulatorischen Interaktion zu teilen.
Interessierte Teilnehmer können sich über den Bereich Veranstaltungen und Präsentationen auf der Investor-Relations-Website von Disc Medicine für die Veranstaltung registrieren. Dieses Treffen stellt einen bedeutenden Schritt im Entwicklungsprozess von Bitopertin als potenzielle Behandlung für EPP-Patienten dar.
- None.
- None.
WATERTOWN, Mass., Jan. 20, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, will host a conference call to discuss feedback received from its Type C meeting on bitopertin in EPP with the U.S. Food and Drug Administration (FDA). The conference call will be held on Tuesday, January 21, at 8:00 am EST.
Conference Call Information
Please register for the event on the Events and Presentations page of Disc’s website at https://ir.discmedicine.com/.
About Bitopertin
Bitopertin is an investigational, clinical-stage, orally administered inhibitor of glycine transporter 1 (GlyT1) that is designed to modulate heme biosynthesis. GlyT1 is a membrane transporter expressed on developing red blood cells and is required to supply sufficient glycine for heme biosynthesis and support erythropoiesis. Disc is planning to develop bitopertin as a potential treatment for a range of hematologic diseases including erythropoietic porphyrias, where it has potential to be the first disease-modifying therapy. Bitopertin has been studied in multiple clinical trials in patients with EPP, including the Phase 2 open-label BEACON trial, the Phase 2 double-blind, placebo-controlled AURORA trial, and an open-label extension HELIOS trial.
Bitopertin is an investigational agent and is not approved for use as a therapy in any jurisdiction worldwide. Disc obtained global rights to bitopertin under a license agreement from Roche in May 2021.
About Erythropoietic Protoporphyria (EPP)
Erythropoietic protoporphyria (EPP), including X-linked Protoporphyria (XLP), is a rare, debilitating and potentially life-threatening disease caused by mutations that affect heme biosynthesis, resulting in the accumulation of a toxic, photoactive intermediate called protoporphyrin IX (PPIX). This causes severe reactions when patients are exposed to sunlight, characterized by excruciating pain, edema, burning sensations and potential blistering and disfigurement. PPIX also accumulates in the hepatobiliary system and can result in complications including gallstones, cholestasis, and liver damage in 20
About Disc Medicine
Disc Medicine is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing novel treatments for patients who suffer from serious hematologic diseases. We are building a portfolio of innovative, potentially first-in-class therapeutic candidates that aim to address a wide spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis. For more information, please visit www.discmedicine.com.
Media Contact
Peg Rusconi
Deerfield Group
peg.rusconi@deerfieldgroup.com
Investor Relations Contact
Christina Tartaglia
Precision AQ
christina.tartaglia@precisionaq.com
FAQ
When is Disc Medicine's (IRON) conference call about the FDA Type C meeting for bitopertin?
What is the purpose of Disc Medicine's (IRON) Type C meeting with the FDA?
How can investors join Disc Medicine's (IRON) conference call about bitopertin?